Journal: Journal of Microbiology and Biotechnology
Article Title: Shiga Toxin Induces Apoptosis via ROS–Caspase Activation in Human Cerebral Endothelial Cell Line hCMEC/D3 and Astrocyte Co-Culture
doi: 10.4014/jmb.2512.12006
Figure Lengend Snippet: ( A ) hCMEC/ D cells were seeded in 6-well plates. Cells were pretreated with z-VAD (20 μM) for 1 h before Stx2a exposure and divided into the following groups: untreated control, Stx2a-treated, z-VAD only, and Stx2a + z-VAD pre-treated. After 24 h of Stx2a treatment, cell viability was assessed using the WST-8 assay ( left panel ). Subsequently, Western blot analysis showed that the total levels of caspase-3/7 in the cell lysates were decreased only in the Stx2a-treated group. Protein samples were prepared using anti-caspase-3, anti-cleaved caspase-3, and anti-β-Actin antibodies ( right panel ). β-Actin was used as a control for equal protein loading; ( B ) hCMEC/D3 cells were seeded as described above and treated with z-VAD 1 h before Stx2a treatment. Cell lysates were harvested from the following groups: untreated control, Stx2a-treated, z-VAD only, and Stx2a + z-VAD pre-treated. Culture supernatants were collected, and the levels of secreted IL-1β, IL-6, IL-8, TNF-α and CCL2 were measured using ELISA ( left panel ). Total RNA was isolated from cell lysates, and mRNA expression levels of IL-1β, IL-6, IL-8, TNF-α, CXCL1, and CCL2 were quantified using RT-qPCR ( right panel ). RNA expression levels were normalized using GAPDH; ( C ) hCMEC/D3 cells were seeded in 6-well plates at a total cell density of 5.0 × 10 5 cells/well and treated with NAC (5μM) 1 h before Stx2a exposure. The experimental groups included control, Stx2a-treated, NAC only, and Stx2a + NAC pre-treated. After 24 h of Stx2a treatment, the cytotoxicity level was measured by LDH assay using the cell culture supernatant. mRNA expression levels of Nrf-2, HO-1, and SOD-2 were measured by RT-qPCR and normalized to GAPDH, and the degree of NO expression was measured by NO assay; ( D ) hCMEC/D3 cells were seeded in 6-well plates at a density of 5.0 × 10 5 cells/well and treated with z-VAD and NAC 1 h before Stx2a treatment. Cell lysates were harvested from the following groups: control, Stx2a-treated, z-VAD + Stx2a, and NAC + Stx2a groups. After 24 h of Stx2 treatment, washed cell lysates were harvested, and the mRNA expression of ZO-1, CLDN3, Occludin and JAM2 were measured using RT-qPCR. RNA expression levels were normalized using GAPDH. Asterisks indicate significant differences compared to the control group, Stx-treated group, or between monotherapy vs. combination therapy (e.g., z-VAD alone vs. z-VAD+Stx2a) (Panels A, B) and compared to the control group, Stx-treated group, or between monotherapy vs. pre-treatment therapy ( e.g. , NAC alone vs. NAC+Stx2a) (Panel C). Significant differences are indicated between the control and cells treated with Stx, Stx+z-VAD, or Stx+NAC (Panel D).* = p < 0.05; ** = p < 0.01; *** = p < 0.001.
Article Snippet: The human brain endothelial cell line hCMEC/D3 (Merck) was cultured in Endothelial Cell Growth Medium (PromoCell, Germany) supplemented with 1% Antibiotic-Antimycotic (Thermo Fisher Scientific, USA), and human astrocyte cell line A172 was cultured in RPMI 1640 medium (Corning, Thermo Fisher Scientific) supplemented with 10% FBS and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific) at 37°C in a humidified incubator containing 5% CO 2 . hCMEC/D3 and A172 cells were seeded at 5.0 × 10 5 cells/well into 6-well plates, washed once with sterile Dulbecco's phosphate-buffered saline (DPBS) (Sigma-Aldrich, USA), and treated with 10 ng/ml Stx2a in Endothelial Cell Growth Medium or RPMI containing 0.5% FBS without supplements for the indicated time periods.
Techniques: Control, Western Blot, Enzyme-linked Immunosorbent Assay, Isolation, Expressing, Quantitative RT-PCR, RNA Expression, Lactate Dehydrogenase Assay, Cell Culture